Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription Articles published in Exp Hematol Retrieve available abstracts of 60 articles: HTML format

Single Articles

August 2026
1. BHOWMIK S, Ghosh S, Sengupta A
   cGAS-STING signaling in acute myeloid leukemia: biology, pathophysiology and therapeutic implications.
   Exp Hematol. 2026 Aug 5:105490. doi: 10.1016/j.exphem.2026.105490.
   PubMed     Abstract available
   
   
   
2. SUZUKI K, Watanabe N, Tsukune Y, Inano T, et al
   Peripheral blood profiles reflecting progenitor lineage balance are associated with molecular response in chronic myeloid leukemia.
   Exp Hematol. 2026 Aug 3:105488. doi: 10.1016/j.exphem.2026.105488.
   PubMed     Abstract available
   
   
   
3. FAGNAN A
   From gamma to X: same destination but different journey?
   Exp Hematol. 2026;160:105445.
   PubMed     Abstract available
   
   
   
4. HASANI R, Pourseif MM, Alizadeh E, Tohidkia MR, et al
   CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances.
   Exp Hematol. 2026;160:105444.
   PubMed     Abstract available
   
   
   July 2026
5. DONADA A
   MYC unchained: dosage-dependent locking of the myeloid fate (or not).
   Exp Hematol. 2026;159:105443.
   PubMed     Abstract available
   
   
   June 2026
6. RAJHANSA S, Crump NT, Khoo HM, Dopico-Fernandez A, et al
   Inhibition of MLLT1 limits growth of KMT2A::AFF1 leukaemias without killing healthy haematopoietic stem cells.
   Exp Hematol. 2026 Jun 3:105458. doi: 10.1016/j.exphem.2026.105458.
   PubMed     Abstract available
   
   
   May 2026
7. STOKES N, Carcamo S, Demircioglu D, Wang X, et al
   Sustained MYC overexpression drives myeloid differentiation block and acquisition of leukemic phenotypes.
   Exp Hematol. 2026;157:105403.
   PubMed     Abstract available
   
   
   
8. DAVID S, Nye GJ, Eudy E, Bolcun-Filas E, et al
   Functional equivalence of gamma- and x-ray irradiation for long-term peripheral blood chimerism and acute myeloid leukemia transplant outcomes in mice.
   Exp Hematol. 2026;157:105385.
   PubMed     Abstract available
   
   
   April 2026
9. ISOBE T, Meggendorfer M, Wolf S, Oellerich T, et al
   Stem11 score: towards rapid clinical prognostication for acute myeloid leukemia.
   Exp Hematol. 2026 Apr 17:105441. doi: 10.1016/j.exphem.2026.105441.
   PubMed     Abstract available
   
   
   
10. SHAH R, Kingston N, Fabbri G, Saeh J, et al
    Evaluation of dual BCL-2/BCL-XL inhibition in acute myeloid leukemia preclinical models with and without prior venetoclax therapy.
    Exp Hematol. 2026;156:105379.
    PubMed     Abstract available
    
    
    March 2026
11. HAMED M, Kovecses O, McKeague M
    Current landscape of mRNA therapeutics for acute myeloid leukemia.
    Exp Hematol. 2026 Mar 17:105406. doi: 10.1016/j.exphem.2026.105406.
    PubMed     Abstract available
    
    
    
12. UEDA K, Sato Y, Minakawa K, Miura S, et al
    Loss of Ezh2 precipitates lethal disease progression in a mouse model of Calr-mutated myeloproliferative neoplasms.
    Exp Hematol. 2026;155:105350.
    PubMed     Abstract available
    
    
    
13. NISHIKII H, Kikuchi R, Kimura T, Saito M, et al
    Tumor necrosis factor from leukemic environment stimulates hematopoietic stem/progenitor cells toward megakaryocyte/myeloid lineage bias.
    Exp Hematol. 2026;155:105332.
    PubMed     Abstract available
    
    
    February 2026
14. LIU X, Zhang Y, Hua S, Shao X, et al
    Gremlin-1 promotes leukemic survival via PI3K/AKT signaling in infant MLL-AF4-positive B-cell acute lymphoblastic leukemia.
    Exp Hematol. 2026 Feb 25:105402. doi: 10.1016/j.exphem.2026.105402.
    PubMed     Abstract available
    
    
    
15. YAN Y, Kato H, Sano S, Furukawa E, et al
    Heme Synthesis Inhibition Induces the Intrinsic Apoptosis Pathway in Leukemia with OSGIN1 Upregulation.
    Exp Hematol. 2026 Feb 13:105401. doi: 10.1016/j.exphem.2026.105401.
    PubMed     Abstract available
    
    
    
16. KHAN AB, Huntly BJP
    Taking the direct route: menin inhibitors go straight to the frontline in KMT2A-rearranged acute leukemia.
    Exp Hematol. 2026 Feb 4:105386. doi: 10.1016/j.exphem.2026.105386.
    PubMed     Abstract available
    
    
    
17. DUGUID A, Malouf C, Nitsche L, Halsey C, et al
    Mixed-lineage leukemia cells undergo unique adaptations in the CNS niche.
    Exp Hematol. 2026;154:105347.
    PubMed     Abstract available
    
    
    
18. IAQUINTA G, Lagana A, Tamburini A, Tatarelli C, et al
    Germline heterozygous SH2B3 p.Glu78Lys variant: a three-patient case series with myeloproliferative neoplasms.
    Exp Hematol. 2026;154:105333.
    PubMed     Abstract available
    
    
    January 2026
19. MAHDAVI L, Alikarami F, Goodrow H, Lenard A, et al
    Upfront menin-inhibitor resistance in multiply pretreated leukemias.
    Exp Hematol. 2026;153:105268.
    PubMed     Abstract available
    
    
    December 2025
20. GORSCH E, Rudat S, Arnone M, Keppeler H, et al
    Laminin Receptor Characterization in Acute Myeloid Leukemia: Integrin alpha7beta1 Defines leukemic cells with Migratory Potential.
    Exp Hematol. 2025 Dec 25:105363. doi: 10.1016/j.exphem.2025.105363.
    PubMed     Abstract available
    
    
    
21. WANG J, Xu J
    Splenic Erythroblasts Fuels Leukemia Progression Through Metabolic Crosstalk.
    Exp Hematol. 2025 Dec 15:105351. doi: 10.1016/j.exphem.2025.105351.
    PubMed     Abstract available
    
    
    November 2025
22. ROY R, Paul T, Das PK, Sinha S, et al
    ERK-mTOR crosstalk suppresses Autophagy and upregulates proteasomal degradation pathway to confer Chronic Myeloid Leukemia cells resistant to Imatinib.
    Exp Hematol. 2025 Nov 28:105330. doi: 10.1016/j.exphem.2025.105330.
    PubMed     Abstract available
    
    
    
23. VARGHESE P, Garcia-Cuellar MP, Slany RK
    The myeloid transcription factor Elf1 regulates genes with function in innate immunity.
    Exp Hematol. 2025;151:104864.
    PubMed     Abstract available
    
    
    October 2025
24. CONNEELY SE, Quezada A, Kurtz KJ, Zhang N, et al
    Cohesin haploinsufficiency is tolerated in Cbfb::MYH11-driven murine acute myeloid leukemia.
    Exp Hematol. 2025 Oct 29:105287. doi: 10.1016/j.exphem.2025.105287.
    PubMed     Abstract available
    
    
    September 2025
25. ERNST P, Kyei P, Yokoyama A
    KMT2A-rearranged leukemia: from mechanism to drug development.
    Exp Hematol. 2025 Sep 6:105247. doi: 10.1016/j.exphem.2025.105247.
    PubMed     Abstract available
    
    
    
26. SANGHA G, Huntly BJP
    Gene regulatory complexes: their role and regulation across normal and malignant hematopoiesis.
    Exp Hematol. 2025;149:104821.
    PubMed     Abstract available
    
    
    
27. YOSHIDA S, Onozawa M, Yokoyama S, Matsukawa T, et al
    Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks.
    Exp Hematol. 2025;149:104819.
    PubMed     Abstract available
    
    
    August 2025
28. WANG J, Xu L, Wang G, Wu W, et al
    ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming.
    Exp Hematol. 2025 Aug 6:104862. doi: 10.1016/j.exphem.2025.104862.
    PubMed     Abstract available
    
    
    
29. SAMAREH B, Klimenkova O, Aghaallaei N, Cheng L, et al
    NAMPT-mediated deacetylation of HCLS1 protein promotes clonogenic growth of pediatric CML cells.
    Exp Hematol. 2025;148:104801.
    PubMed     Abstract available
    
    
    July 2025
30. FOSSELTEDER J, Brauchart T, Schlacher A, Sconocchia T, et al
    Engineered cytokine-expressing MSCs support ex vivo culture of human HSPCs and AML cells.
    Exp Hematol. 2025;147:104790.
    PubMed     Abstract available
    
    
    June 2025
31. ZHANG A, Qiu S
    Advances of RARalpha fusion genes in acute promyelocytic leukemia.
    Exp Hematol. 2025 Jun 7:104822. doi: 10.1016/j.exphem.2025.104822.
    PubMed     Abstract available
    
    
    May 2025
32. LU J, Xue X, Wang H, Hao Y, et al
    Notch1 activation and inhibition in T cell acute lymphoblastic leukemia subtypes.
    Exp Hematol. 2025 May 8:104771. doi: 10.1016/j.exphem.2025.104771.
    PubMed     Abstract available
    
    
    
33. CISA-WIECZOREK S, Hernandez-Alvarez MI, Parreno M, Munoz JP, et al
    D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1.
    Exp Hematol. 2025;145:104748.
    PubMed     Abstract available
    
    
    April 2025
34. FOURNIER M, Dubuissez M, Neault M, Delisle JS, et al
    Unbiased analysis of NUP98-KDM5A-induced murine leukemia reveals phenotypic heterogeneity recapitulating human disease subtypes.
    Exp Hematol. 2025 Apr 19:104791. doi: 10.1016/j.exphem.2025.104791.
    PubMed     Abstract available
    
    
    March 2025
35. GUL AZ, Selek S, Bekiroglu S, Demirel M, et al
    Serum NMR metabolomics in distinct subtypes of hematologic malignancies.
    Exp Hematol. 2025;143:104710.
    PubMed     Abstract available
    
    
    
36. SARCHI M, Doulatov S
    Understanding Human Oncogene Function and Cooperativity in Myeloid Malignancy Using iPSCs.
    Exp Hematol. 2025;143:104697.
    PubMed     Abstract available
    
    
    
37. GUIRGUIS AA
    RNA methylation: where to from here for hematologic malignancies?
    Exp Hematol. 2025;143:104694.
    PubMed     Abstract available
    
    
    February 2025
38. TACHIBANA T, Izumi A, Arai S, Takeda T, et al
    Preconditioning intervention before allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Exp Hematol. 2025 Feb 12:104746. doi: 10.1016/j.exphem.2025.104746.
    PubMed     Abstract available
    
    
    
39. DE GROOT AP, Nguyen H, Pouw JS, Weersing E, et al
    CBX7 inhibitors affect H3K9 methyltransferase-regulated gene repression in leukemic cells.
    Exp Hematol. 2025;142:104691.
    PubMed     Abstract available
    
    
    January 2025
40. AMOR AR, Enlund S, Sinha I, Jiang Q, et al
    A Distinct Alternative mRNA Splicing Profile Identifies the Oncogenic CD44 Transcript Variant 3 in KMT2A-Rearranged Pediatric T-cell Acute Lymphoblastic Leukemia Cells.
    Exp Hematol. 2025 Jan 8:104712. doi: 10.1016/j.exphem.2025.104712.
    PubMed     Abstract available
    
    
    November 2024
41. QU Y, Shourabizadeh H, Subramanian A, Aleman DM, et al
    DIFFERENTIAL IMPACT OF CD34+ CELL DOSE FOR DIFFERENT AGE GROUPS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A MACHINE LEARNING-BASED DISCOVERY.
    Exp Hematol. 2024 Nov 22:104684. doi: 10.1016/j.exphem.2024.104684.
    PubMed     Abstract available
    
    
    October 2024
42. KOHNKE T, Feng Y, Majeti R
    A New Era of Functional Experimentation in Human Hematopoiesis and Leukemia Research.
    Exp Hematol. 2024 Oct 1:104652. doi: 10.1016/j.exphem.2024.104652.
    PubMed     Abstract available
    
    
    September 2024
43. KHAMARI R, Degand C, Fovez Q, Trinh A, et al
    Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors.
    Exp Hematol. 2024;137:104253.
    PubMed     Abstract available
    
    
    August 2024
44. CAMIOLO G, Mullen CG, Ottersbach K
    Mechanistic insights into the developmental origin of pediatric hematologic disorders.
    Exp Hematol. 2024;136:104583.
    PubMed     Abstract available
    
    
    June 2024
45. ONG KOK, Mok MMH, Niibori-Nambu A, Du L, et al
    Activation of NOTCH signaling impedes cell proliferation and survival in acute megakaryoblastic leukemia.
    Exp Hematol. 2024 Jun 12:104255. doi: 10.1016/j.exphem.2024.104255.
    PubMed     Abstract available
    
    
    
46. STRAUBE J, Janardhanan Y, Haldar R, Bywater MJ, et al
    Immune control in acute myeloid leukemia.
    Exp Hematol. 2024 Jun 12:104256. doi: 10.1016/j.exphem.2024.104256.
    PubMed     Abstract available
    
    
    
47. ROGERS JH, Rosen A, Reyes JM, Ketkar S, et al
    Dose-dependent effects of Dnmt3a in an inducible murine model of Kras(G12D)-driven leukemia.
    Exp Hematol. 2024 Jun 2:104248. doi: 10.1016/j.exphem.2024.104248.
    PubMed     Abstract available
    
    
    
48. XU JJ, Viny AD
    Chromatin organization in myelodysplastic syndrome.
    Exp Hematol. 2024;134:104216.
    PubMed     Abstract available
    
    
    May 2024
49. ZHOU Q, Li Z, Xi Y
    EV-mediated intercellular communication in acute myeloid leukemia: Transport of genetic materials in the bone marrow microenvironment.
    Exp Hematol. 2024;133:104175.
    PubMed     Abstract available
    
    
    March 2024
50. PANTING RG, Kotecha RS, Cheung LC
    The critical role of the bone marrow stromal microenvironment for development of drug screening platforms in leukemia.
    Exp Hematol. 2024 Mar 27:104212. doi: 10.1016/j.exphem.2024.104212.
    PubMed     Abstract available
    
    
    
51. GOSWAMI M, Bose PD
    Gut Microbial Dysbiosis in the Pathogenesis of Leukemia: An Immune-based Perspective.
    Exp Hematol. 2024 Mar 23:104211. doi: 10.1016/j.exphem.2024.104211.
    PubMed     Abstract available
    
    
    
52. LIU Q, Zhai Y, Hui Y, Chen J, et al
    Identification of Red blood cell distribution width as a prognostic factor in acute myeloid leukemia.
    Exp Hematol. 2024 Mar 18:104206. doi: 10.1016/j.exphem.2024.104206.
    PubMed     Abstract available
    
    
    February 2024
53. TANAKA T, Kudo K, Kanezaki R, Yuzawa K, et al
    Anti-leukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome.
    Exp Hematol. 2024 Feb 9:104179. doi: 10.1016/j.exphem.2024.104179.
    PubMed     Abstract available
    
    
    
54. RANDALL J, Evans K, Watts B, Kosasih HJ, et al
    IN VIVO ACTIVITY OF THE SECOND-GENERATION PROTEASOME INHIBITOR IXAZOMIB AGAINST PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS.
    Exp Hematol. 2024 Feb 4:104176. doi: 10.1016/j.exphem.2024.104176.
    PubMed     Abstract available
    
    
    
55. MERZ AMA, Platzbecker U
    Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms.
    Exp Hematol. 2024;130:104130.
    PubMed     Abstract available
    
    
    December 2023
56. ALQAZZAZ MA, Luciani GM, Vu V, Machado RM, et al
    Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
    Exp Hematol. 2023 Dec 8:S0301-472X(23)01773-3. doi: 10.1016/j.exphem.2023.
    PubMed     Abstract available
    
    
    
57. BUROCZIOVA M, Grusanovic S, Vanickova K, Kosanovic S, et al
    Chronic inflammation promotes cancer progression as a second hit.
    Exp Hematol. 2023;128:30-37.
    PubMed     Abstract available
    
    
    October 2023
58. XIE Y, Tan L, Wu K, Li D, et al
    MiR-455-3p mediates PPARalpha through UBN2 to promote apoptosis and autophagy in acute myeloid leukemia cells.
    Exp Hematol. 2023 Oct 5:S0301-472X(23)01734-4. doi: 10.1016/j.exphem.2023.
    PubMed     Abstract available
    
    
    September 2023
59. GUARNERA L, Santinelli E, Galossi E, Cristiano A, et al
    Microenvironment in Acute Myeloid Leukemia: focus on senescence mechanisms, therapeutic interactions and future directions.
    Exp Hematol. 2023 Sep 21:S0301-472X(23)01705.
    PubMed     Abstract available
    
    
    
60. HAN L, Wu J, Lyu X, Yu J, et al
    Genetic Mutation Signature for Relapse Prediction in Normal Karyotype Acute Myeloid Leukemia.
    Exp Hematol. 2023 Sep 20:S0301-472X(23)01706.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum